Distinguished in Gliosarcoma

Dr. Adilia M. Hormigo

Neurology | Oncology | Hematology
Montefiore Medical Center
111 E 210th St, 
Bronx, NY 
Clinical Trials:Currently Recruiting for 1 Trial
Distinguished in Gliosarcoma
Montefiore Medical Center
111 E 210th St, 
Bronx, NY 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Adilia Hormigo is a Neurologist and an Oncologist in Bronx, New York. Dr. Hormigo is rated as a Distinguished provider by MediFind in the treatment of Gliosarcoma. Her top areas of expertise are Glioblastoma, Astrocytoma, Glioma, Brain Tumor, and Myringotomy.

Her clinical research consists of co-authoring 28 peer reviewed articles and participating in 7 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, she has participated in 1 clinical trial in the study of Gliosarcoma.

Specialties
Neurology
Oncology
Hematology
Licenses
Psychiatry & Neurology in NY
Hospital Affiliations
Montefiore Medical Center
Languages Spoken
English
Gender
Female

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Cigna
  • EPO
  • HMO
  • PPO
Health First
  • HMO
  • POS
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D

Locations

MONTEFIORE MEDICAL CENTER
111 E 210th St, Bronx, NY 10467

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

7 Clinical Trials

Phase II Trial of SMO/ AKT/ NF2/CDK Inhibitors in Progressive Meningiomas With SMO/ AKT/ NF2/CDK Pathway Mutations
Phase II Trial of SMO/ AKT/ NF2/CDK Inhibitors in Progressive Meningiomas With SMO/ AKT/ NF2/CDK Pathway Mutations
Enrollment Status: Recruiting
Publish Date: October 08, 2025
Intervention Type: Drug
Study Drugs: Vismodegib, GSK2256098, Capivasertib, Abemaciclib
Study Phase: Phase 2
Phase I Study of Tumor Treatment Fields and a Personalized Mutation-derived Tumor Vaccine in Patients With Newly Diagnosed Glioblastoma (GCO 17-0566)
Phase I Study of Tumor Treatment Fields and a Personalized Mutation-derived Tumor Vaccine in Patients With Newly Diagnosed Glioblastoma (GCO 17-0566)
Enrollment Status: Active_not_recruiting
Publish Date: September 10, 2025
Intervention Type: Biological, Drug, Device
Study Drugs: Poly-ICLC, Peptides
Study Phase: Phase 1
A Phase II/III Randomized Trial of Veliparib or Placebo in Combination With Adjuvant Temozolomide in Newly Diagnosed Glioblastoma With MGMT Promoter Hypermethylation
A Phase II/III Randomized Trial of Veliparib or Placebo in Combination With Adjuvant Temozolomide in Newly Diagnosed Glioblastoma With MGMT Promoter Hypermethylation
Enrollment Status: Active_not_recruiting
Publish Date: July 30, 2025
Intervention Type: Other, Drug
Study Drugs: Temozolomide, Veliparib
Study Phase: Phase 2/Phase 3
A Phase 3 Randomized Double-blind, Controlled Study of ICT-107 With Maintenance Temozolomide (TMZ) in Newly Diagnosed Glioblastoma Following Resection and Concomitant TMZ Chemoradiotherapy
A Phase 3 Randomized Double-blind, Controlled Study of ICT-107 With Maintenance Temozolomide (TMZ) in Newly Diagnosed Glioblastoma Following Resection and Concomitant TMZ Chemoradiotherapy
Enrollment Status: Suspended
Publish Date: April 03, 2024
Intervention Type: Biological
Study Phase: Phase 3
Phase I Study of PD-L1 Inhibition With Avelumab and Laser Interstitial Thermal Therapy in Patients With Recurrent Glioblastoma
Phase I Study of PD-L1 Inhibition With Avelumab and Laser Interstitial Thermal Therapy in Patients With Recurrent Glioblastoma
Enrollment Status: Completed
Publish Date: January 04, 2022
Intervention Type: Combination product, Drug
Study Drugs: Avelumab, MRI-guided LITT therapy
Study Phase: Phase 1
A Toll-like Receptor Agonist as an Adjuvant to Tumor Associated Antigens (TAA) Mixed With Montanide ISA-51 VG With Bevacizumab for Patients With Recurrent Glioblastoma
A Toll-like Receptor Agonist as an Adjuvant to Tumor Associated Antigens (TAA) Mixed With Montanide ISA-51 VG With Bevacizumab for Patients With Recurrent Glioblastoma
Enrollment Status: Withdrawn
Publish Date: January 13, 2020
Intervention Type: Drug, Biological
Study Phase: Phase 2
A Phase 3, Randomized, Controlled, Double-Arm, Open-Label, Multi-center Study of VB-111 Combined With Bevacizumab vs. Bevacizumab Monotherapy in Patients With Recurrent Glioblastoma
A Phase 3, Randomized, Controlled, Double-Arm, Open-Label, Multi-center Study of VB-111 Combined With Bevacizumab vs. Bevacizumab Monotherapy in Patients With Recurrent Glioblastoma
Enrollment Status: Completed
Publish Date: October 23, 2018
Intervention Type: Drug
Study Phase: Phase 3
View 6 Less Clinical Trials

28 Total Publications

Multiparametric Radiogenomic Model to Predict Survival in Patients with Glioblastoma.
Multiparametric Radiogenomic Model to Predict Survival in Patients with Glioblastoma.
Journal: Cancers
Published: January 08, 2024
Similar Doctors
Elite in Gliosarcoma
Dr. Deric Park
Neurology | Hematology | Oncology
Elite in Gliosarcoma
Dr. Deric Park
Neurology | Hematology | Oncology

Regional Cancer Care Associates LLC

92 2nd St, 
Hackensack, NJ 
 (9.1 miles away)
201-996-5900
Languages Spoken:
English
See accepted insurances

Deric Park is a Neurologist and a Hematologist in Hackensack, New Jersey. Dr. Park is rated as a Distinguished provider by MediFind in the treatment of Gliosarcoma. His top areas of expertise are Gliosarcoma, Astrocytoma, Glioblastoma, and Glioma.

Distinguished in Gliosarcoma
Dr. Fabio M. Iwamoto
Neurology
Distinguished in Gliosarcoma
Dr. Fabio M. Iwamoto
Neurology

Trustees Of Columbia University In The City Of New York

710 W 168th St, 
New York, NY 
 (4.2 miles away)
212-305-3870
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Fabio Iwamoto is a Neurologist in New York, New York. Dr. Iwamoto is rated as an Elite provider by MediFind in the treatment of Gliosarcoma. His top areas of expertise are Glioblastoma, Astrocytoma, Glioma, and Brain Tumor.

Distinguished in Gliosarcoma
Dr. Howard A. Fine
Oncology | Neurology
Distinguished in Gliosarcoma
Dr. Howard A. Fine
Oncology | Neurology

Weill Medical College Of Cornell

525 E 68th St, 
New York, NY 
 (8.9 miles away)
212-746-2323
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Howard Fine is an Oncologist and a Neurologist in New York, New York. Dr. Fine is rated as an Elite provider by MediFind in the treatment of Gliosarcoma. His top areas of expertise are Astrocytoma, Glioblastoma, Glioma, and Brain Tumor.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Hormigo's expertise for a condition
ConditionClose
View All 8 Distinguished Conditions
View All 7 Advanced Conditions
View All 16 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile